Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol...

by Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux, Jonathan Wadsley
Published 2019-06-01